EU Panel Backs Maintenance Rucaparib for Ovarian Cancer

December 13, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. The positive opinion is based on findings from the phase III … (leggi tutto)